Study guide
7.3 Transfusion Reactions: Investigation Protocol and Reaction Classification
AMT Medical Laboratory Scientist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: General Laboratory Operations, Safety & Quality
1.1 Laboratory Safety, OSHA Standards, Hazard Communication, and Biohazard Control 1.2 Quality Systems, Quality Control, and Westgard Rules Interpretation 1.3 Specimen Collection, Handling, Order of Draw, and Phlebotomy Complications 1.4 Laboratory Instrumentation, Photometry, Spectrophotometry, and Centrifugation 1.5 Laboratory Mathematics, Dilutions, Solution Preparation, and Standard Curves 1.6 Regulatory Compliance, CLIA '88 Regulations, Accreditation, and Laboratory Ethics
2 Chapter 2: Clinical Chemistry & Metabolic Testing
2.1 Carbohydrate Metabolism, Glucose Regulation, Diabetes Mellitus, and HbA1c 2.2 Proteins, Non-Protein Nitrogenous Compounds (BUN, Creatinine, Uric Acid), and Renal Function 2.3 Enzymology and Organ Systems 2.4 Electrolytes, Acid-Base Balance, Anion Gap, and Blood Gas Analysis 2.5 Clinical Endocrinology, Thyroid, Adrenal, and Reproductive Hormones 2.6 Clinical Toxicology, Therapeutic Drug Monitoring (TDM), and Pharmacokinetics 2.7 Lipids, Lipoproteins, and the Friedewald LDL Calculation
3 Chapter 3: Hematology & Leukocyte Disorders
3.1 RBC Indices and Anemia 3.2 WBC Differential and Benign Disorders 3.3 Hematologic Malignancies 3.4 Hemoglobin Structure, Hemoglobinopathies (Sickle Cell, Thalassemia), and Variants 3.5 Hematology Automation, Flow Cytometry, and Cell Counting Technology
4 Chapter 4: Coagulation & Hemostasis
4.1 Primary and Secondary Hemostasis, Platelet Function, and Vascular Integrity 4.2 Coagulation Cascade Disorders 4.3 Coagulation Testing and Anticoagulants
5 Chapter 5: Immunology & Serology
5.1 Immune Mechanisms, Hypersensitivity Reactions, and Autoimmune Disease Testing 5.2 Serological Testing Principles and Infectious Serology
6 Chapter 6: Immunohematology & Blood Grouping
6.1 ABO and Rh Blood Group Systems, Antigens, Subgroups, and Weak D Variant 6.2 Red Cell Antibody Screening, Identification Panels, and Dosage Effects 6.3 Direct and Indirect Antiglobulin Testing (DAT/IAT) and Troubleshooting 6.4 Compatibility Testing, Crossmatching, and Hemolytic Disease of the Fetus and Newborn
7 Chapter 7: Blood Banking & Transfusion Medicine
7.1 Blood Donor Selection, Screening, Collection, and Component Storage 7.2 Transfusion Practice, Indications for Blood Components, and Administration 7.3 Transfusion Reactions: Investigation Protocol and Reaction Classification
8 Chapter 8: Clinical Microbiology
8.1 Specimen Processing, Gram Stain, and Aerobic Gram-Positive Cocci 8.2 Gram-Negative Bacilli: Enterobacteriaceae, Non-Fermenters, and Fastidious Organisms 8.3 Anaerobic Bacteria, Mycobacteria, Acid-Fast Stains, and Molecular Diagnostic Methods 8.4 Clinical Mycology and Medical Parasitology 8.5 Antimicrobial Susceptibility Testing, Resistance, and Virology
9 Chapter 9: Urinalysis & Body Fluids
9.1 Physical and Chemical Examination of Urine and Reagent Strip Principles 9.2 Microscopic Urinalysis: Cells, Casts, Crystals, and Renal Pathology 9.3 Analysis of Cerebrospinal Fluid (CSF), Serous Fluids, and Synovial Fluid
7.3 Transfusion Reactions: Investigation Protocol and Reaction Classification
Key Takeaways Explain This Topic AI
The first step in any suspected transfusion reaction is to STOP the transfusion immediately while keeping the IV line open with normal saline.
An Acute Hemolytic Transfusion Reaction (AHTR) is a life-threatening ABO incompatibility often caused by clerical error, presenting with fever, chills, back pain, and hemoglobinuria.
Febrile Non-Hemolytic Transfusion Reaction (FNHTR) involves a 1°C temperature rise caused by recipient antibodies against donor leukocytes or accumulated cytokines; leukoreduction mitigates this.
TRALI (Transfusion-Related Acute Lung Injury) is a leading cause of transfusion-related mortality, triggered by donor anti-HLA or anti-HNA antibodies causing noncardiogenic pulmonary edema.
The laboratory investigation protocol mandates a clerical check, visual inspection of post-reaction plasma for hemolysis, and performing a Direct Antiglobulin Test (DAT).
Last updated: July 2026
Transfusion Reactions and Investigation Protocol
Despite stringent safety measures, adverse events related to blood transfusions can occur. Transfusion reactions range from mild allergic responses to fatal hemolytic events. Rapid recognition and a systematic laboratory investigation are essential to manage the patient and prevent similar occurrences.
Immediate Actions: The Transfusion Reaction Protocol
When a transfusion reaction is suspected (e.g., patient complains of chills, pain, shortness of breath, or fever), the clinical staff must act immediately:
STOP the transfusion immediately. This is unequivocally the most important first step.
Keep the IV line open by infusing normal saline (0.9% NaCl).
Check all labels, tags, and patient identification wristbands for any clerical errors .
Notify the attending physician and the blood bank.
Send the remaining blood unit and tubing back to the blood bank.
Draw a post-reaction blood sample (EDTA tube) carefully to avoid mechanical hemolysis, and collect a post-reaction urine sample .
Laboratory Investigation
Upon receiving the post-reaction samples and blood unit, the blood bank initiates a standardized workup to rule out a hemolytic event.
Clerical Check : Verify all paperwork, labels, and computer records. Clerical errors are the leading cause of fatal hemolytic reactions.
Visual Inspection : Centrifuge the post-reaction blood sample and visually compare the plasma/serum to the pre-reaction sample. Pink or red plasma indicates hemoglobinemia (intravascular hemolysis). Icteric (yellow) plasma may indicate delayed hemolysis.
Direct Antiglobulin Test (DAT) : Perform a DAT on the post-reaction red cells. A positive DAT (mixed field) indicates that antibodies have attached to the transfused donor cells in vivo.
ABO/Rh Confirmation : Repeat the ABO and Rh typing on the post-reaction sample and compare it to the pre-reaction sample and the donor unit.
Urine Check : Test the post-reaction urine for free hemoglobin (hemoglobinuria).
If the DAT is positive, or hemolysis is visually evident, the blood bank must proceed to elution, antibody screening, and crossmatching to identify the specific incompatibility.
- Classification of Transfusion Reactions
- Acute Hemolytic Transfusion Reaction (AHTR)
Mechanism : Immune-mediated destruction of donor red cells, usually due to ABO incompatibility (e.g., Group A blood given to a Group O patient). IgM antibodies activate complement fully, causing rapid intravascular hemolysis.
Symptoms : Fever, chills, lower back/flank pain (due to kidney involvement), hypotension, hemoglobinuria, and a feeling of impending doom. It can progress to Disseminated Intravascular Coagulation (DIC) and renal failure.
Lab Findings : Positive DAT, visible hemolysis in plasma, decreased haptoglobin, and hemoglobin in urine.
Febrile Non-Hemolytic Transfusion Reaction (FNHTR)
Mechanism : Most commonly caused by recipient antibodies attacking donor human leukocyte antigens (HLA) or by cytokines that accumulate in the blood component during storage.
Symptoms : A temperature rise of >= 1°C above baseline, accompanied by chills or rigors, without any evidence of hemolysis.
Prevention : Provision of leukoreduced blood products significantly reduces the incidence of FNHTR.
Allergic and Anaphylactic Reactions
Mechanism : Mild allergic reactions (urticaria/hives) are caused by recipient antibodies reacting to donor plasma proteins. Severe anaphylactic reactions occur in patients who are IgA-deficient and have developed anti-IgA antibodies; when exposed to IgA in donor plasma, they rapidly develop shock.
Symptoms :
Mild : Hives, itching, erythema (can often be treated with antihistamines and the transfusion restarted if only urticaria is present).
Severe : Bronchospasm, wheezing, profound hypotension, absent fever.
Prevention : Washed cellular products (to remove plasma) for known IgA-deficient patients.
Transfusion-Related Acute Lung Injury (TRALI)
Mechanism : A leading cause of transfusion-related mortality. It is triggered by donor antibodies (anti-HLA or anti-HNA) in the plasma of the blood product that react with the recipient's white blood cells. These WBCs aggregate in the pulmonary vasculature, causing capillary leakage and noncardiogenic pulmonary edema.
Symptoms : Acute respiratory distress, severe hypoxemia, and bilateral pulmonary infiltrates on chest X-ray within 6 hours of transfusion.
Prevention : Deferring female donors with a history of pregnancy from donating plasma products, as they are most likely to possess these alloantibodies.
Transfusion-Associated Circulatory Overload (TACO)
Mechanism : Non-immune volume overload resulting from infusing blood products too rapidly or in too high a volume, overwhelming the patient's cardiovascular system (common in elderly patients, infants, or those with underlying heart/renal failure).
Symptoms : Dyspnea, orthopnea, tachycardia, hypertension, and pulmonary edema.
Differentiation from TRALI : TACO is characterized by hypertension and an elevated BNP (Brain Natriuretic Peptide), whereas TRALI is often associated with hypotension and normal BNP. TACO responds well to diuretics.
Understanding these distinct reactions ensures rapid, appropriate medical intervention and prevents catastrophic outcomes in transfusion medicine.